Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate AstraZeneca plc (ADR) before investing.

In this article, we go over a few key elements for understanding AstraZeneca plc (ADR)’s stock price such as:

• AstraZeneca plc (ADR)’s current stock price and volume
• Why AstraZeneca plc (ADR)’s stock price changed recently
• Upgrades and downgrades for AZN from analysts
• AZN’s stock price momentum as measured by its relative strength

About AstraZeneca plc (ADR) (AZN)

Before we jump into AstraZeneca plc (ADR)’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, the Americas and Asia, Africa and Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.

Want to learn more about AstraZeneca plc (ADR)’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about AstraZeneca plc (ADR).

AstraZeneca plc (ADR)’s Stock Price as of Market Close

As of February 08, 2024, 4:00 PM, CST, AstraZeneca plc (ADR)’s stock price was $63.52.

AstraZeneca plc (ADR) is down 4.55% from its previous closing price of $66.55.

During the last market session, AstraZeneca plc (ADR)’s stock traded between $66.49 and $66.90. Currently, there are 3,098.00 million shares of AstraZeneca plc (ADR) stock available for purchase.

AstraZeneca plc (ADR)’s price-earnings (P/E) ratio is currently at 35.2, which is high compared to the Pharmaceuticals industry median of 25.3. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

AstraZeneca plc (ADR) Stock Price History

AstraZeneca plc (ADR)’s (AZN) price is currently down 4.68% so far this month.

During the month of February, AstraZeneca plc (ADR)’s stock price has reached a high of $67.09 and a low of $61.70.

Over the last year, AstraZeneca plc (ADR) has hit prices as high as $76.56 and as low as $61.73. Year to date, AstraZeneca plc (ADR)’s stock is down 6.31%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused AstraZeneca plc (ADR) Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 07, 2024, there was 1 analyst who downgraded AstraZeneca plc (ADR)’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate AstraZeneca plc (ADR)’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on AstraZeneca plc (ADR)’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

AstraZeneca plc (ADR)’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about AstraZeneca plc (ADR) (AZN) by visiting AAII Stock Evaluator.

Relative Price Strength of AstraZeneca plc (ADR)

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 07, 2024, AstraZeneca plc (ADR) has a weighted four-quarter relative price strength of -3.99%, which translates to a Momentum Score of 59 and is considered to be Average.

Want to learn more about how AstraZeneca plc (ADR) is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

AstraZeneca plc (ADR) Stock Price: Bottom Line

As of February 8, 2024, AstraZeneca plc (ADR)’s stock price is $63.52, which is down 4.55% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like AstraZeneca plc (ADR) stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.